PDCD1 and metastatic neoplasm: The effect of the combination of Wee1 inhibitor ZN-c3 with PD1 inhibitor Pembrolizumab will also be studied in patients with solid tumors with advanced or metastatic disease at the clinical trial NCT04158336.